COVID-19 is significantly less dangerous at the population level than it was in 2020 and 2021, but not primarily because the virus itself has become milder. The biggest shift comes from widespread immunity built through vaccination and prior infections. In 2024, the estimated infection fatality rate in a well-vaccinated country like Austria was 0.048%, a fraction of the 1% or higher rates seen during the first pandemic waves. For most people, a COVID infection today looks and feels very different from what it did four years ago.
Why COVID Feels Milder Now
The improvement in outcomes is largely an immunity story. After multiple rounds of infection and vaccination, most adults carry immune memory that prevents the virus from reaching the lungs and causing severe pneumonia. A study tracking people with hybrid immunity (meaning they had both vaccination and a natural infection) found that protective antibodies remained strong for at least a year, and none of the participants who got reinfected during the study developed severe disease.
This pattern mirrors what evolutionary biologists predicted early in the pandemic. A widely cited model showed that as people build immunity through childhood infections and boosters, population-level mortality drops substantially over time, even without the virus becoming inherently less dangerous. The key insight: immunity that prevents severe illness lasts much longer than immunity that prevents infection altogether. So you can still catch COVID, but your body is far better equipped to keep it from becoming life-threatening.
The Virus Hasn’t Necessarily Become Gentler
There’s a common assumption that viruses always evolve to become less harmful. The reality with SARS-CoV-2 is more complicated. Evolutionary biologists have outlined three possible paths: the virus could trend toward lower severity, higher severity that optimizes transmission, or an unpredictable middle ground. Early variants like Alpha were actually more virulent than the original strain, not less. The apparent mildness of more recent waves has more to do with the immune landscape of the population than with changes in the virus itself.
Data from hospitalized children under five, a group with less prior immunity, illustrates this. Across pre-Delta, Delta, and Omicron periods, ICU admission rates held steady at about 20 to 21%, and the proportion needing mechanical ventilation stayed at 7 to 8%. Among those who ended up hospitalized, the severity of illness didn’t meaningfully improve from one variant era to the next. What changed was how many people got sick enough to need a hospital bed in the first place.
Current Fatality and Hospitalization Numbers
In Austria’s nationwide analysis of 2024 data, the overall infection fatality rate was 0.048%. For context, the early pandemic IFR was estimated at roughly 0.5 to 1.0% in many countries before vaccines were available. The steepest remaining risk sits with the oldest populations: nursing home residents aged 85 and older had an IFR around 1.0 to 1.2%, while community-dwelling adults aged 60 to 74 faced rates of just 0.03%.
Hospitalization rates in the United States during the 2024 to 2025 season were low enough that the CDC couldn’t generate reliable estimates for vaccine effectiveness against critical illness (ICU admission, ventilation, or death) simply because there weren’t enough severe cases to study. That alone signals how far things have come.
Long COVID Risk Has Dropped
One of the most feared consequences of infection, long COVID, also appears less common with recent variants. A pooled analysis of 35 studies covering 159,000 participants across 19 countries found that long COVID prevalence dropped from 35.5% during pre-Omicron waves to 22.8% during the Omicron period. That’s still a substantial number, meaning roughly one in four to five people with an Omicron-era infection reported lingering symptoms, but the trend is moving in the right direction. The reduction likely reflects both changes in the dominant variants and higher levels of population immunity at the time of infection.
How Well Vaccines and Treatments Work Now
The updated 2024 to 2025 COVID vaccine provided about 45 to 46% protection against hospitalization for adults 65 and older during the first four months after vaccination. For older adults with weakened immune systems, that number was around 40%. These figures are more modest than the 90%-plus efficacy seen with the original vaccines against the original virus, but they reflect the challenge of targeting a virus that keeps shifting its surface proteins. Protection against the most severe outcomes, including death, has historically been higher and longer-lasting than protection against hospitalization alone.
Antiviral treatment remains useful for high-risk patients but with important caveats. In the original clinical trial of unvaccinated, high-risk adults, the leading antiviral reduced hospitalizations and deaths by about 5.6 percentage points. In a real-world study of vaccinated patients in British Columbia, the benefit was smaller: a 2.5 percentage point reduction for the highest-risk group and 1.7 points for the next tier down. For people at only moderate risk, the benefit was not statistically significant. In practical terms, antiviral treatment matters most for people who are elderly, immunocompromised, or have multiple serious health conditions.
Where Things Stand in 2025
The World Health Organization ended COVID’s status as a public health emergency of international concern in May 2023 and has since folded its COVID reporting into a standing dashboard rather than issuing dedicated situation reports. COVID is now tracked alongside other respiratory viruses like influenza and RSV, a shift that reflects its transition from crisis to ongoing public health concern.
For most healthy adults with some immune history from vaccines or prior infections, COVID in 2025 is a manageable illness. It still kills tens of thousands of people each year, disproportionately the elderly and immunocompromised, and long COVID continues to affect a meaningful share of those infected. But the combination of population-wide immunity, updated vaccines, and available treatments has turned what was once a global emergency into something closer to a serious seasonal respiratory infection. The situation is genuinely better. It just isn’t over.